Related Experiment Videos
Effect of eicosapentaenoic acid in asthma
C M Kirsch1, D G Payan, M Y Wong
1Department of Medicine, University of California, San Francisco 94143.
Clinical Allergy
|March 1, 1988
Summary
Dietary eicosapentaenoic acid (EPA) supplementation did not improve asthma symptoms or lung function in patients. This study found no significant changes in clinical status or pulmonary function after 8 weeks of EPA intake.
Area of Science:
- Pulmonary Medicine
- Clinical Nutrition
- Immunology
Background:
- Arachidonic acid metabolites are implicated in airway inflammation and asthma pathogenesis.
- Eicosapentaenoic acid (EPA) produces less potent metabolites compared to arachidonic acid.
- Substituting EPA metabolites for arachidonic acid metabolites may reduce airway inflammation and improve asthma.
Purpose of the Study:
- To investigate the effect of dietary eicosapentaenoic acid (EPA) supplementation on airway inflammation and clinical asthma.
- To assess changes in clinical status and pulmonary function in asthmatic patients receiving EPA.
Main Methods:
- Twelve asthmatic patients participated in the study.
- Patients received either low-dose (0.1 g/day) or high-dose (4.0 g/day) EPA for 8 weeks (weeks 6-14).
- Clinical evaluations and pulmonary function tests were conducted at baseline and multiple time points throughout the study.
Main Results:
- No significant differences in clinical status or pulmonary function were observed between the low-dose and high-dose EPA groups at the study's start.
- There were no statistically significant changes in clinical status or pulmonary function within or between the groups after 8 weeks of EPA ingestion.
Conclusions:
- Dietary supplementation with eicosapentaenoic acid (EPA) did not demonstrate a therapeutic benefit for asthma.
- Further research may be needed to explore alternative omega-3 fatty acids or different dosages for potential asthma management.